Company Description
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease.
The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001.
Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jun 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Stephan Jackman |
Contact Details
Address: 3480 Peachtree Road NE, Second Floor, Suite 103 Atlanta, Georgia 30326 United States | |
| Phone | 844 722 6333 |
| Website | alzamend.com |
Stock Details
| Ticker Symbol | ALZN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001677077 |
| CUSIP Number | 02262M308 |
| ISIN Number | US02262M4078 |
| Employer ID | 81-1822909 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephan Jackman | Chief Executive Officer and Director |
| Milton Charles Ault III | Founder and Vice Chairman |
| David J. Katzoff | Chief Financial Officer |
| Henry C. W. Nisser Esq. | Executive Vice President, General Counsel and Director |
| Kenneth S. Cragun CPA | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2025 | 424B3 | Prospectus |
| Apr 8, 2025 | EFFECT | Notice of Effectiveness |
| Mar 27, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 19, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 13, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 13, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 10, 2025 | 10-Q | Quarterly Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 28, 2025 | PRE 14A | Other preliminary proxy statements |